TY - JOUR
T1 - A Thieno[2,3- d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D 2 Receptor
AU - Fyfe, Tim J.
AU - Zarzycka, Barbara
AU - Lim, Herman D.
AU - Kellam, Barrie
AU - Mistry, Shailesh N.
AU - Katrich, Vsevolod
AU - Scammells, Peter J.
AU - Lane, J. Robert
AU - Capuano, Ben
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Recently, a novel negative allosteric modulator (NAM) of the D 2 -like dopamine receptors 1 was identified through virtual ligand screening. This ligand comprises a thieno[2,3-d]pyrimidine scaffold that does not feature in known dopaminergic ligands. Herein, we provide pharmacological validation of an allosteric mode of action for 1, revealing that it is a NAM of dopamine efficacy and identify the structural determinants of this allostery. We find that key structural moieties are important for functional affinity and negative cooperativity, while functionalization of the thienopyrimidine at the 5- and 6-positions results in analogues with divergent cooperativity profiles. Successive compound iterations have yielded analogues exhibiting a 10-fold improvement in functional affinity, as well as enhanced negative cooperativity with dopamine affinity and efficacy. Furthermore, our study reveals a fragment-like core that maintains low μM affinity and robust negative cooperativity with markedly improved ligand efficiency.
AB - Recently, a novel negative allosteric modulator (NAM) of the D 2 -like dopamine receptors 1 was identified through virtual ligand screening. This ligand comprises a thieno[2,3-d]pyrimidine scaffold that does not feature in known dopaminergic ligands. Herein, we provide pharmacological validation of an allosteric mode of action for 1, revealing that it is a NAM of dopamine efficacy and identify the structural determinants of this allostery. We find that key structural moieties are important for functional affinity and negative cooperativity, while functionalization of the thienopyrimidine at the 5- and 6-positions results in analogues with divergent cooperativity profiles. Successive compound iterations have yielded analogues exhibiting a 10-fold improvement in functional affinity, as well as enhanced negative cooperativity with dopamine affinity and efficacy. Furthermore, our study reveals a fragment-like core that maintains low μM affinity and robust negative cooperativity with markedly improved ligand efficiency.
UR - http://www.scopus.com/inward/record.url?scp=85046490671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046490671&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.7b01565
DO - 10.1021/acs.jmedchem.7b01565
M3 - Article
C2 - 29683325
AN - SCOPUS:85046490671
VL - 62
SP - 174
EP - 206
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
SN - 0022-2623
IS - 1
ER -